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Compounding pharmacies have been cited by some athletes as being responsible for compounding 
capsules contaminated with drugs banned by the International Olympic Committee (IOC). Therefore, the 
present study was carried out to quantify the amount of residue remaining in the equipment and utensils 
used for compounding capsules after standard cleaning procedures. For this purpose, captopril (CAP) 
and acetylsalicylic acid (ASA) were used since these are hard to clean, in addition to hydrochlorothiazide 
(HTZ) as a banned drug by the IOC. The amounts of residues found in the equipment were: 181.0 ± 91.8, 
1208 ± 483.8 and 431.7 ± 71.3 ppm for ASA, CAP and HTZ, respectively. The continuous compounding 
of these drugs, followed each time by the standard cleaning procedure, showed a linear accumulation 
of residues for ASA (r2=0.96) and CAP (r2= 0.88). The residues quantified were greater than the FDA 
limit for impurities for CAP (>0.1%) but not for HTZ. However, the HTZ residue may be detected in 
the urine of athletes on IOC tests. Therefore, it was concluded that compounding pharmacies should 
therefore improve their cleaning procedures and test these in order to attain limits below 10 ppm, thereby 
avoiding the contamination of other products.
Uniterms: Compounding pharmacy/cleaning procedure/equipments. Pharmacy equipaments/cleaning. 
Pharmaceutical products/contamination. Captopril. Acetylsalicylic acid. Hydrochlorothiazide.
As farmácias de manipulação têm sido citadas por alguns atletas como sendo responsáveis pela manipulação 
de cápsulas contaminadas com fármacos proibidos pelo Comitê Olímpico Internacional (COI). Portanto, 
o presente estudo foi realizado para quantificar o montante de resíduo remanescente nos equipamentos e 
utensílios usados para manipular cápsulas após o procedimento padrão de limpeza. Para este propósito, o 
captopril (CAP) e o ácido acetilsalicílico (ASA) foram usados por serem fármacos de difícil remoção e a 
hidroclorotiazida (HTZ), por ser um fármaco proibido pelo COI. As quantidades de resíduos encontradas 
nos equipamentos após a limpeza foram 181,0 ± 91,8, 1208 ± 483,8 e 431,7 ± 71,3 ppm para ASA, CAP 
e HTZ, respectivamente. A manipulação contínua dos fármacos seguida pelo procedimento de limpeza 
mostrou acúmulo de resíduo linear para ASA (r2=0,96) e CAP (r2=0,88). A quantidade de resíduo de CAP 
foi maior que o limite de impureza sugerido pelo FDA (>0,1%), mas não para HTZ, mas mesmo assim, 
o resíduo de HTZ pode ser detectado na urina dos atletas submetidos aos testes do COI. Em conclusão, 
as farmácias de manipulação deveriam, portanto, melhorar o procedimentos de limpeza e testá-los para 
que alcancem limites abaixo de 10 ppm para evitar contaminação nos outros produtos.
Unitermos: Farmácia de manipulação/procedimentos de limpeza/equipamentos. Equipamentos 
farmacêuticos/limpeza. Produtos farmacêuticos/contaminação. Captopril. Ácido acetilsalicílico. 
Hidroclorotiazida.
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INTRODUCTION
The Football World Cup in 2014 and the Olympic 
Games in 2016 will be hosted by Brazil, and in the quest 
to be the strongest and fastest, many athletes consume 
different nutritional and energetic supplements and, in 
some cases, performance-enhancing drugs forbidden by the 
International Olympic Committee (IOC) (Müller, 2010).
Traces of diuretics are commonly found in the urine 
samples of athletes, such as in the case of a swimming gold 
medalist who alleged he had ingested nutritional supplements 
contaminated with prohibited substances compounded by a 
local pharmacy (ESPN, 2011), and of a paralympic athlete 
who consumed green tea capsules contaminated with a 
banned diuretic (IPC, 2012). Based on these claims, they 
received a light penalty and a 9-month suspension for 
anti-doping rule violation, respectively, and the reliability 
of all compounding pharmacies was called into question.
The handling of different medicines is inherent in the 
pharmaceutical profession and plays an important role in 
the care of individual patients; however, debates often arises 
over errors and adverse events caused by inappropriately 
compounded formulations, resulting in risk to the patient 
and possible legal action (Gudeman et al., 2013).
The USP 34 chapter 795 (USP, 2011) and the Good 
Compounding Practices for Pharmacies edited by the 
Brazilian Health Surveillance Agency (ANVISA, 2006) 
recommend that equipment and utensils be cleaned and 
formulations compounded in a clean environment, but 
no confirmation of recovery of residues is required after 
cleaning procedures, as is required for drug manufacturing 
laboratories (FDA, 1993).
To date, no reports demonstrating the amount of 
residues remaining on utensils and equipment used by 
compounding pharmacies have been published. Therefore, 
the objective of this study was to quantity the residues 
recovered from pestle-and-mortar and encapsulation devices 
used for mixing powders and filling capsules after standard 
cleaning procedures used by the majority of compounding 
pharmacies in Brazil. Based on the criterion of being hard 
to clean, captopril (CAP) and acetylsalicylic acid (ASA) 
were chosen because they strongly adhere to surfaces and 
are unstable in water, along with hydrochlorothiazide (HTZ) 
because it is banned by the IOC.
MATERIAL AND METHODS
Spectrophotometric UV-Vis validation methods
Standard Solution Preparation
Stock solutions of CAP, ASA and HTX were 
prepared to a final concentration of 100 mg/L by dissolving 
25 mg of active substances (USP Reference Standard) 
in 0.1 N hydrochloride acid solution, 2 mL of ethanol 
and further dilution with 0.05 M pH 4.5 acetate buffer or 
0.1 M sodium hydroxide solutions, respectively, in 250 mL 
volumetric flasks and used immediately. The calibration 
curves were built at concentrations of 10, 15, 20, 30, 50 
and 70 mg/L for ASA and 1, 5, 10, 15 and 20 mg/L for 
both CAP and HTZ. The absorbances were measured 
at wavelengths of 212, 265 and 275 nm for CAP, ASA, 
and HTZ, respectively, using a model UVmini-1240 
UV-Vis-spectrophotometer (Shimadzu, Japan).
Validation
The validation procedure was carried out according 
to the Guidance for Industry – the Analytical Method 
Validation recommended by the U.S. Food and Drug 
Administration (FDA, 2000).
Pharmaceuticals and compounding products
-  ASA: capsules containing 100 mg ASA and 100 mg 
of starch
-  CAP: capsules containing 25 mg CAP and 100 mg 
of lactose 
-  HTZ: capsules containing 25 mg HTZ and 100 mg 
of lactose
The active compounds were weighed and mixed with 
the amount of excipient required to fill 60 capsules. Each 
compound was mixed with lactose (CAP and HTZ) or starch 
(ASA) in a mortar (outer diameter 10 cm, depth 5 cm) by 
rotating a pestle clockwise 10 times and anti-clockwise 
10 times. After mixing the active compounds with the 
excipients, each powder mix was spread onto the tray of 
the encapsulation device and the capsules were filled. This 
compounding sequence was carried out in triplicate.
Cleaning procedure and drug recovery
The cleaning procedure followed the standard 
operating procedure (SOP) used by 3 different 
compounding pharmacies in Maringá city, Paraná 
State, Brazil was followed in the study. Briefly, the 
manual encapsulation devices (Capsutec, Brazil) were 
disassembled after routine compounding and the trays 
cleaned with dry paper wipes and then with paper wipes 
moistened with 70% alcohol, and dried with a hair dryer. 
The same cleaning procedure was followed for the mortar 
and pestles. At the end of each day, the encapsulation 
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TABLE I - Validation parameters of spectrophotometric methods 
for the drugs
Parameters ASA CAP HTZ
Linearity (mg/L) 8 – 30 1 – 20 1 – 20
R2 0.9992 0.9991 0.9998
Accuracy (%) 96.8 ± 3.3 100.7 ± 0.2 99.6 ± 3.7
Precision (%) 3.97 0.72 2.65
LOQ (mg/L) 0.91 0.33 0.03
LDQ (mg/L) 3.03 0.10 1.02
LOQ and LDQ denote Limit of Quantification and Limit of 
Detection, respectively.
TABLE II - Residues recovered after one compounding procedure 
followed by standard cleaning procedure
Drugs
Encapsulation 
Device 
Mean ± SD
Pestle & Mortar 
Mean ± SD
ASA (ppm) 181.0 ± 91.8 33.8 ± 3.5
CAP (ppm) 1208.0 ± 483.8 385.3 ± 47.3
HTZ (ppm) 431.7± 71.3 363.0 ± 77.6
The ppm values represent 1 mg of residue remaining after 
compounding 1 g of active compound, and are expressed as 
Mean and Standard Deviation (SD) after triplicate assays.
devices were disassembled and all component parts were 
immersed in water for 15 minutes, washed with detergent 
and a brush, rinsed with tap water followed by distilled 
water then immersed in 70% alcohol solution for 15 
minutes and allowed to dry in a 40 oC chamber.
The recovery procedure of the residues from the 
encapsulation devices was carried out after standard 
cleaning with dry paper wipes. The disassembled devices 
were rinsed into a tray containing 500 mL of the same 
solvents used to quantify each of the active compound 
described in the validation method, in order to minimize 
solvent interferences or stability problems during the 
analysis, maximize drug solubility and improve recovery. 
The trays were stirred for 10 minutes at 50 rpm and the 
solvents were collected, filtered and the residues analyzed 
by the UV-Vis spectrophotometer method. To determine 
the accumulation of residues after repeated compounding 
procedures of the same compound, the same procedure 
(compounding, cleaning, drying, rinsing, filtering and 
UV-Vis analysis) was carried out after 1, 3, 5 and 7 
compounding procedures and a linear regression method 
was applied using Microsoft Excel 2010 to ascertain 
whether the residues increased proportionally to the 
number of compounding procedures.
For the drug recovery procedure from mortar-and-
pestle residues, 50 mL of the solvents used to quantify 
the active substances in the validation method were used 
and slow rotations performed to remove the residues. The 
solvents were then filtered and analyzed by the UV-Vis 
spectrophotometer method.
The concentrations of the recovered residues 
were calculated from the absorbance measured for each 
sample and plotted on their respective calibration curve 
to determine the final concentration of the residues. In 
order to determine the total residue amount remaining 
in the encapsulation device after standard cleaning, the 
calculated concentration of each sample was multiplied 
by 500 (dilution factor = 500 mL) and then transformed 
into ppm (parts per million, namely, the proportion of each 
microgram of residue recovered after compounding and 
cleaning for each gram of active substance, e.g. CAP or 
HTZ =25 mg active substance x 60 capsules = 1.5 g). The 
dilution factor for pestle and mortar was 50.
The compounding procedures, followed by cleaning 
and recovery procedures, were carried out three times for 
each active substance and the mean and standard deviation 
calculated using Microsoft Excel.
RESULTS AND DISCUSSION
This study shows that after performing standard 
cleaning of compounding equipment, large quantities 
of residues were recovered for all of the drugs tested, 
and that these residues can contaminate the next product 
compounded using the same equipment.
The analytical method of UV-Vis spectrophotometry 
was chosen because most compounding pharmacies 
cannot afford high-performance liquid-chromatography 
equipment but have a spectrophotometer in their 
laboratories.
The spectrophotometric validation of the active 
ingredients used in this study followed the methods 
described by the USP 34 - dissolution test (Table I) and 
all procedures met the requirements of the analytical-
validation methods. The linearity concentrations were 
based on the lower limit for contamination accepted by 
the FDA of below 10 ppm.
High quantities of residues were found for all drugs 
on the encapsulation devices and pestle and mortar after 
the standard cleaning procedure had been carried out by 
trained technicians. The average amount recovered from 
the encapsulation device and mortar and pestle after one 
compounding procedure for ASA, CAP and HTZ are 
shown in Table II.
T. Prioste, T. F. S. Magon, V. Fagundes, M. C. Montanha, C. Moriwaki1, E. Kimura320
The residues in the next product were not measured 
because of limitations of the analytical method used, 
but alternatively, the residues accumulated after several 
compounding and cleaning procedures of the same active 
ingredient were quantified. Also, to avoid contaminant 
residues from previous compounding procedures, 
the encapsulation devices were washed, dried and 
tested by checking whether any residue could be 
quantified.
A linear correlation given by the coefficient 
r2 was found between the number of compounding 
procedures and the amount of accumulated residue for 
CAP (r2=0.8837) and ASA (r2=0.9596), but not for HTZ 
(r2 = 0.0538), on the encapsulation devices (Figure 1).
The amounts of residues recovered after cleaning 
the devices were very high and have the potential to 
contaminate other products.
This is the first time the amount of residue remaining 
after standard cleaning procedures of compounding 
devices used by compounding pharmacies has been 
quantified. With regard to toxicity, the quantities of 
residues found in this study show that these drugs are not 
likely to be toxic to patients of subsequently compounded 
products. However, for athletes, these quantities of 
residues are sufficient to contaminate subsequent products 
and be detected in the urine or plasma of the athletes given 
the highly sensitive analytical methods used by the IOC, 
such as mass spectrometry and immunochemical methods, 
whose sensitivity limits are measured in picograms and 
femtograms (Deventer et al., 2009).
Each compounding pharmacy adopts their own 
cleaning procedure and verification of the cleaning 
procedure is usually carried out by visual examination; that 
is, checking that no residue particles are visible. However, 
this does not guarantee that equipment is free of residues. 
FDA guidelines recommend a maximum drug contaminant 
limit of 0.1% or 1000 ppm for cleaning validation 
procedures, but do not consider drug contaminants 
in the same way as impurities such as heavy metals, 
chlorides, sulfates and arsenic, whose maximum levels 
must be below 10 ppm in raw materials. Nevertheless, 
some pharmaceutical manufacturers have established 
contaminant levels for their cleaning validation approval 
of below 10 ppm in subsequent products, or 1/1000 of the 
minimum daily dose of the active compound in relation 
to the maximum daily dose of the subsequent product 
(LeBlanc, 2002).
If the residue limits of 0.1% or 1000 ppm are 
followed, the cleaning procedures used by the compounding 
pharmacies would meet FDA requirement for ASA and 
HTZ, but not for CAP. Adoption of 10 ppm as a limit would 
FIGURE 1 - Residues of acetylsalicylic acid, captopril and 
hydrochlorothiazide after consecutive compounding and 
cleaning procedures. *ppm values represent 1 microgram of 
residue remaining after compounding 1 g of active compound, 
and are expressed as the mean and SD after triplicate assays.
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be more appropriate, as the drug levels in blood or urine 
after intake of capsules contaminated with < 10 ppm of 
residue would be close to the quantification and detection 
limits, even when using the most sensitive detection 
methods such as chromatography mass spectrometry 
(Thevis, Thomas, Schanzer, 2013). Furthermore, the most 
important outcome for the compounding pharmacies is 
that they would not be responsible for contaminating 
products with banned drugs.
Washing the equipment is time-consuming as it 
takes a long time to dry all the component parts. However, 
because of the high volume of preparations being 
compounded using different ingredients, these devices 
must be available quickly and having one encapsulation 
device for every formulation is not economically 
viable.
Cleaning validation procedures should, therefore, 
also be recommended for non-sterile products from 
compounding pharmacies, with “the hardest to clean” 
criteria being adopted, encompassing hydrophobic 
or unstable drugs or those that strongly adhere to 
surfaces.
In order to achieve a high level of quality in 
compounding pharmacy preparations, the standard 
cleaning procedure of equipment should be improved and 
reviewed in order to remove the vast majority of residues 
adhered to surfaces and cavities of encapsulation devices.
CONCLUSIONS
The quantity of residues recovered from the 
encapsulation devices after the standard cleaning 
procedures used by the compounding pharmacies in our 
study, may be sufficiently high to contaminate the next 
compounded product, where these contaminants may 
subsequently be detected in urine samples using highly 
sensitive methods. Cleaning procedures should, therefore, 
be improved in order to keep residue amounts below the 
10 ppm limit.
ACKNOWLEDGEMENTS
The authors would like to thank the Fundação 
Araucária and the Science and Technology Secretariat 
of Paraná State, Brazil, for financial support. We would 
also like to thank pharmacist Eliane Tabuti for technical 
assistance and Peter J. Grimshaw for translating the 
manuscript to English.
REFERENCES
ANVISA. Agência Nacional de Vigilância Sanitária. Guias 
da Qualidade. Available at: <http://www.anvisa.gov.br/
inspecao/guias_qualidade>. Acessed on: 14 Jan 2014.
DEVENTER, K.; POZO, O.J.; VAN EENOO, P.; DELBEKE, 
F.T. Detection of urinary markers for thiazide diuretics after 
oral administration of hydrochlorothiazide and altizide-
relevance to doping control analysis. J. Chromatogr, v.1216, 
n.12, p.2466-2473, 2009.
ESPN. Entertainment and Sports Programming Network. 
Cesar Cielo’s pharmacy blamed. Available at: <http://
espn.go.com/olympics/swimming/story/_/id/6815407/
pharmacy-blamed-world-champion-swimmer-cesar-cielo-
positive-doping-test>. Accessed on: 14 Jan 2014.
FDA. U.S. Food and Drug Administration. Validation of 
Cleaning Processes (7/93). Available at: <http://www.fda.
gov/ICECI/Inspections/InspectionGuides/ ucm074922.
htm>. Acessed on: 14 Jan 2014.
FDA. U.S. Food and Drug Administration. Guidance for 
Industry Analytical Procedures and Methods Validation. 
Available at: http://www.fda.gov/downloads/Drugs/
Guidances/ ucm122858.pdf. Accessed on: 14 Jan 2014.
GUDEMAN, J.; JOZWIAKOWSKI, M.; CHOLLET, J.; 
RANDELL, M. Potential risks of pharmacy compounding. 
Drugs, v.13, p.1-8, 2013.
IPC. INTERNATIONAL PARAOLYMPIC COMMITTEE. 
Brazilian Athlete Sanctioned after Anti-Doping Rule 
Violation. Available at: http://www.paralympic.org/press-
release/brazilian-athlete-sanctioned-after-anti-doping-rule-
violation. Accessed on: 14 Jan 2014.
LEBLANC, D.A. ‘Visually clean’ as a sole acceptance criterion 
for cleaning validation protocols. PDA J. Pharm. Sci. Tech., 
v.56, p.31-36, 2002.
MÜLLER, R.K. History of doping and doping control. In: 
THIEME, D.; HEMMERSBACK, P. (Eds.) Doping in 
sports. Handbook of experimental pharmacology, n.195. 
Berlin Heidelberg: Springer-Verlag, 2010. p.01-23. 
T. Prioste, T. F. S. Magon, V. Fagundes, M. C. Montanha, C. Moriwaki1, E. Kimura322
THEVIS, M.; THOMAS, A.; SCHANZER, W. Targeting 
prohibited substances in doping control blood samples by 
means of chromatographic-mass spectrometric methods. 
Anal. Bioanal. Chem v.405, p.9655-9667, 2013.
UNITED STATES PHARMACOPOEIA. USP. The United 
States Pharmacopeial Convention 34.ed, 2011. Available at: 
http://www.usp.org/sites/default/files/usp_pdf/EN/gc795.
pdf. Acessed on: 14 Jan 2014.
Received for publication on 06th February 2014
Accepted for publication on 18th June 2014
